Bicara Therapeutics Common Stock Current Asset
| BCAX Stock | 20.79 0.17 0.81% |
Bicara Therapeutics Common fundamentals help investors to digest information that contributes to Bicara Therapeutics' financial success or failures. It also enables traders to predict the movement of Bicara Stock. The fundamental analysis module provides a way to measure Bicara Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bicara Therapeutics stock.
Non Current Assets Total is likely to drop to about 2.5 M in 2024. Other Current Assets is likely to drop to about 583.6 K in 2024. Bicara |
Bicara Therapeutics Common Company Current Asset Analysis
Bicara Therapeutics' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Bicara Current Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Bicara Therapeutics is extremely important. It helps to project a fair market value of Bicara Stock properly, considering its historical fundamentals such as Current Asset. Since Bicara Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bicara Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bicara Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
In accordance with the recently published financial statements, Bicara Therapeutics Common has a Current Asset of 0.0. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run FinTech Suite Now
FinTech SuiteUse AI to screen and filter profitable investment opportunities |
| All Next | Launch Module |
Bicara Fundamentals
| Current Valuation | 577.25 M | ||||
| Shares Outstanding | 54.39 M | ||||
| Shares Owned By Insiders | 0.42 % | ||||
| Number Of Shares Shorted | 2.07 M | ||||
| Price To Book | 2.15 X | ||||
| EBITDA | (58.3 M) | ||||
| Total Debt | 382.75 M | ||||
| Book Value Per Share | (5.10) X | ||||
| Earnings Per Share | (3.75) X | ||||
| Market Capitalization | 1.1 B | ||||
| Total Asset | 233.98 M | ||||
| Retained Earnings | (153.02 M) | ||||
| Working Capital | 215.99 M | ||||
| Net Asset | 233.98 M |
About Bicara Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bicara Therapeutics Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bicara Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bicara Therapeutics Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Bicara Stock Analysis
When running Bicara Therapeutics' price analysis, check to measure Bicara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicara Therapeutics is operating at the current time. Most of Bicara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicara Therapeutics' price. Additionally, you may evaluate how the addition of Bicara Therapeutics to your portfolios can decrease your overall portfolio volatility.